Adnexus Therapeutics, Inc.: Considering the Exit

內容大綱
Dr. John Mendlein, CEO of Adnexus Therapeutics Inc., (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month collaboration or continue with Adnexus' planned IPO.
涵蓋主題
新增
新增